Puma Biotechnology Inc (NYSE:PBYI) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Friday.

Other research analysts have also recently issued reports about the company. Citigroup Inc. raised Puma Biotechnology to a “buy” rating and set a $105.00 target price for the company in a research report on Sunday, May 28th. Royal Bank Of Canada raised their target price on Puma Biotechnology from $40.00 to $60.00 and gave the stock a “sector perform” rating in a research report on Thursday, May 25th. J P Morgan Chase & Co reaffirmed a “buy” rating on shares of Puma Biotechnology in a research report on Tuesday, July 18th. Stifel Nicolaus reiterated a “buy” rating and set a $118.00 price objective (up from $105.00) on shares of Puma Biotechnology in a research note on Tuesday, July 18th. Finally, Zacks Investment Research lowered Puma Biotechnology from a “buy” rating to a “hold” rating in a research note on Wednesday, June 7th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $108.90.

Shares of Puma Biotechnology (PBYI) opened at 107.40 on Friday. The firm’s 50-day moving average is $88.12 and its 200 day moving average is $63.32. The company’s market cap is $4.00 billion. Puma Biotechnology has a 1-year low of $28.35 and a 1-year high of $107.65.

Puma Biotechnology (NYSE:PBYI) last issued its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($2.10) EPS for the quarter, missing the consensus estimate of ($1.32) by $0.78. Equities analysts expect that Puma Biotechnology will post ($8.60) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Puma Biotechnology Inc (PBYI) Raised to Buy at BidaskClub” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.watchlistnews.com/puma-biotechnology-inc-pbyi-raised-to-buy-at-bidaskclub/1548009.html.

In other news, SVP Richard Paul Bryce sold 5,000 shares of the firm’s stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $87.10, for a total value of $435,500.00. Following the completion of the sale, the senior vice president now directly owns 34,237 shares in the company, valued at $2,982,042.70. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Adage Capital Partners Gp, L.L sold 247,260 shares of the firm’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $80.32, for a total value of $19,859,923.20. The disclosure for this sale can be found here. Insiders have sold 267,433 shares of company stock valued at $21,732,262 over the last quarter. Corporate insiders own 22.70% of the company’s stock.

Large investors have recently made changes to their positions in the company. Strs Ohio acquired a new stake in shares of Puma Biotechnology in the second quarter valued at $122,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Puma Biotechnology in the second quarter valued at $146,000. Bank of Montreal Can acquired a new stake in shares of Puma Biotechnology in the first quarter valued at $195,000. Alambic Investment Management L.P. acquired a new stake in shares of Puma Biotechnology in the first quarter valued at $201,000. Finally, Kazazian Asset Management LLC acquired a new stake in shares of Puma Biotechnology in the second quarter valued at $209,000. Institutional investors own 80.98% of the company’s stock.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Analyst Recommendations for Puma Biotechnology (NYSE:PBYI)

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.